Deloitte July 31, 2020
Mark Lush, Christopher Zant, Sherilyn Notte Tuthill, Alicia Saddock

The life sciences industry is moving beyond core patient services to the next generation of engagement platforms that seamlessly span the entire patient life cycle to help improve health outcomes.

IN our 2016 article Patient engagement strategies in a digital environment, we described life sciences companies’ essential opportunity to make a meaningful impact on patients’ lives by engaging more closely with them.1 At that time, various technologies were being launched to help make patient engagement more holistic and seamless across the spectrum of emergent tools, including patient services platforms, wearable monitoring devices, mobile wellness apps, and the like.

Many life sciences companies were embarking on transforming their organizations, people, processes, and platforms to strengthen patient engagement with a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech
Avenzo, BioAge-backer Sands Capital raises new $555M life sciences fund
Results are in from Wegovy's longest trial yet: 2 new findings
AI database to bolster research for GLP1-RAs as precision medicines
Quantum Health Launches New Pharmacy Navigation Solution for Employers
Weight loss drugs and surgery complications: New study

Share This Article